Patents by Inventor Mitchell E. Reff

Mitchell E. Reff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Expression and use of anti-CD20 Antibodies
    Patent number: 7744877
    Abstract: Disclosed herein are methods of depleting peripheral blood B cells in a human host comprising administering to the host an immunologically active anti-CD20 antibody in an amount effective to deplete peripheral blood B cells in the host.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: June 29, 2010
    Assignee: Biogen Idec Inc.
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
    Patent number: 7695940
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: April 13, 2010
    Assignee: Biogen Idec MA Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES AND USE THEREOF AS THERAPEUTICS
    Publication number: 20090069553
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: August 17, 2007
    Publication date: March 12, 2009
    Applicant: Biogen Idec Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES AND USE THEREOF AS THERAPEUTICS
    Publication number: 20090061511
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: August 17, 2007
    Publication date: March 5, 2009
    Applicant: BIOGEN IDEC INC.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES AND USE THEREOF AS THERAPEUTICS
    Publication number: 20090018314
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: August 17, 2007
    Publication date: January 15, 2009
    Applicant: Biogen Idec Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
    Patent number: 7438906
    Abstract: Methods for inhibiting production of IgE in a human subject with an IgE-mediated allergic disorder by administering anti-CD23 antibodies.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: October 21, 2008
    Assignee: Biogen Idec MA Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Anti-CD20 antibodies
    Patent number: 7422739
    Abstract: Disclosed are chimeric, immunologically active, isolated, and radiolabeled antibodies directed against the CD20 antigen. The antibodies are useful for treating and diagnosing B cell disorders.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: September 9, 2008
    Assignee: Biogen Idec Inc.
    Inventors: Darrell R. Anderson, Nabil Hanna, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES AND USE THEREOF AS THERAPEUTICS
    Publication number: 20080193447
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: August 17, 2007
    Publication date: August 14, 2008
    Applicant: Biogen Idec Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Expression and use of anti-CD20 antibodies
    Patent number: 7381560
    Abstract: Disclosed are immunologically active antibodies directed against the CD20 antigen, as well as host cells comprising nucleic acid sequences encoding the light chains and heavy chains of immunologically active antibodies wherein the cell is capable of expressing and secreting an immunologically active chimeric anti-CD20 antibody and methods of using such host cells to make purified antibodies. The antibodies are useful for treating and diagnosing B cell disorders.
    Type: Grant
    Filed: July 25, 2001
    Date of Patent: June 3, 2008
    Assignee: Biogen Idec Inc.
    Inventors: Darrell R. Anderson, Nabil Hanna, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
    Patent number: 7332163
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Grant
    Filed: September 28, 2004
    Date of Patent: February 19, 2008
    Assignee: Biogen Idec Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
    Patent number: 7223392
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: May 29, 2007
    Assignee: Biogen Idec MA Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • ?-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
    Patent number: 7033589
    Abstract: Methods for inhibiting production of IgE in a human subject with an IgE-mediated allergic disorder by administering anti-CD23 antibodies.
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: April 25, 2006
    Assignee: Biogen Idec MA Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
    Patent number: 6893636
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Grant
    Filed: February 5, 1998
    Date of Patent: May 17, 2005
    Assignee: Biogen Idec MA Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
    Patent number: 6682734
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 27, 2004
    Assignee: IDEC Pharmaceuticals Corporation
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
    Publication number: 20030147885
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Application
    Filed: September 11, 2002
    Publication date: August 7, 2003
    Applicant: IDEC PHARMACEUTICALS CORPORATION
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restriced differentiation antigen for treatment of B cell lymphoma
    Publication number: 20030095963
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Application
    Filed: July 25, 2001
    Publication date: May 22, 2003
    Applicant: IDEC Pharmaceuticals Corporation
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES AND USE THEREOF AS THERAPEUTICS
    Publication number: 20030086921
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: February 5, 1998
    Publication date: May 8, 2003
    Inventors: MITCHELL E. REFF, WILLIAM S. KLOETZER, TAKEHIKO NAKAMURA
  • Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
    Publication number: 20030082172
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Application
    Filed: March 14, 2002
    Publication date: May 1, 2003
    Applicant: IDEC PHARMACEUTICALS
    Inventors: Darrell R. Anderson, Nabil Hanna, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Inhibition of apoptosis process and improvement of cell performance
    Publication number: 20030064510
    Abstract: The present invention relates to preventing or delaying programmed cell death by expressing one or more anti-apoptotic polypeptides in a cell such that programmed cell death in the cell is prevented or delayed. The present invention also relates to increasing production of a cell-related product by expressing one or more anti-apoptotic polypeptides in a cell such that production of the cell-related product by the cell is increased. Recombinant cells useful for producing cell-related product or cellular therapy are also provided.
    Type: Application
    Filed: July 10, 2002
    Publication date: April 3, 2003
    Applicant: IDEC Pharmaceuticals Corporation
    Inventors: Mitchell E. Reff, Eric Ailor, Michael J. Betenbaugh, Bruno Figueroa, Marie Hardwick
  • Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
    Publication number: 20030059424
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: March 25, 2002
    Publication date: March 27, 2003
    Applicant: IDEC Pharmaceutical Corporation
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura